Truqap (Capivasertib) Tablets

Truqap (capivasertib), from AstraZeneca, is a first-in-class oral AKT inhibitor. It is approved in combination with fulvestrant for adults with hormone receptor (HR)-positive, HER2-negative, locally advanced or metastatic breast cancer harboring one or more PIK3CA, AKT1, or PTEN alterations, following progression on at least one endocrine-based regimen.

A newer indication covers PTEN-deficient metastatic castration-resistant prostate cancer, based on the CAPItello-281 trial (approved June 2026 — verify current label wording before relying on this).

Capivasertib is an ATP-competitive inhibitor of all three AKT isoforms (AKT1, AKT2, AKT3), blocking the PI3K/AKT/PTEN signalling pathway that drives survival and proliferation in tumors with pathway-activating alterations.

• Hyperglycemia: blood glucose should be monitored, especially in patients with diabetes or risk factors.
• Diarrhea can be severe; antidiarrheal treatment and dose modification may be needed.
• Cutaneous reactions (rash) are common and may require dose interruption.
• Pneumonitis/interstitial lung disease has been reported.
• Embryo-fetal toxicity: effective contraception is required during treatment.

What documents are required to import Truqap to India?

Truqap may be imported in the patient’s name only, by patients or government hospitals. The following documentation is required:

• A valid prescription from a registered oncologist
• Tumor biomarker test report confirming PIK3CA/AKT1/PTEN alteration or PTEN deficiency
• Patient ID proof (issued by the Government of India)

How is the order confirmed?

The order is confirmed only after receipt and verification of a valid prescription and biomarker test report, and an import permit, if applicable.

Is Truqap available in India?

Truqap is a prescription medicine that legally requires a doctor’s prescription to be dispensed. It is not commercially marketed in India. Patients in India can legally access Truqap through the Named Patient Program (NPP).

Indian Pharma Network (IPN) can source Truqap from reliable channels across the world and facilitate supply to patients, doctors, and hospitals under applicable legal provisions. All prescriptions are dispensed and checked by registered pharmacists.

For Truqap cost in India and availability, contact IPN at Phone: +91-9310090915 or email info@indianpharmanetwork.in.

Global Approval Status:

• United States: Approved by the FDA — November 16, 2023 (breast cancer); June 2026 (prostate cancer, verify current status).

What is the generic name for the brand drug Truqap?

Capivasertib is the generic name for the brand drug Truqap.

What is Truqap used for?

Truqap is used with fulvestrant for certain PIK3CA/AKT1/PTEN-altered HR+/HER2- breast cancers, and for PTEN-deficient metastatic prostate cancer.

Who manufactures Truqap?

Truqap is manufactured by AstraZeneca.

Do I need biomarker testing before starting Truqap?

Yes — Truqap requires confirmed PIK3CA/AKT1/PTEN alteration (or PTEN deficiency) via an approved test.

How much does Truqap cost in India?

Cost depends on sourcing country, quantity, and logistics. Share your prescription with IPN for an itemized quote.